These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacological and SAR analysis of the LINS01 compounds at the human histamine H Corrêa MF; Barbosa ÁJR; Fernandes GAB; Baker JG; Fernandes JPDS Chem Biol Drug Des; 2019 Jan; 93(1):89-95. PubMed ID: 30153371 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of potent pyrrolidine H(3) antagonists. Vasudevan A; Conner SE; Gentles RG; Faghih R; Liu H; Dwight W; Ireland L; Kang CH; Esbenshade TA; Bennani YL; Hancock AA Bioorg Med Chem Lett; 2002 Nov; 12(21):3055-8. PubMed ID: 12372500 [TBL] [Abstract][Full Text] [Related]
6. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds. Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253 [TBL] [Abstract][Full Text] [Related]
7. D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist. Curtis MP; Dwight W; Pratt J; Cowart M; Esbenshade TA; Krueger KM; Fox GB; Pan JB; Pagano TG; Hancock AA; Faghih R; Bennani YL Arch Pharm (Weinheim); 2004 Apr; 337(4):219-29. PubMed ID: 15146898 [TBL] [Abstract][Full Text] [Related]
8. Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Aslanian R; Mutahi Mw; Shih NY; Piwinski JJ; West R; Williams SM; She S; Wu RL; Hey JA Bioorg Med Chem Lett; 2003 Jun; 13(12):1959-61. PubMed ID: 12781173 [TBL] [Abstract][Full Text] [Related]
9. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity. Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966 [TBL] [Abstract][Full Text] [Related]
10. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699 [TBL] [Abstract][Full Text] [Related]
11. Diamine derivatives containing imidazolidinylidene propanedinitrile as a new class of histamine H3 receptor antagonists. Part I. Sasho S; Seishi T; Kawamura M; Hirose R; Toki S; Shimada JI Bioorg Med Chem Lett; 2008 Apr; 18(7):2288-91. PubMed ID: 18353639 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists. Gfesser GA; Zhang H; Dinges J; Fox GB; Pan JB; Esbenshade TA; Yao BB; Witte D; Miller TR; Kang CH; Krueger KM; Bennani YL; Hancock AA; Faghih R Bioorg Med Chem Lett; 2004 Feb; 14(3):673-6. PubMed ID: 14741266 [TBL] [Abstract][Full Text] [Related]
14. Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds. Stark H; Sadek B; Krause M; Hüls A; Ligneau X; Ganellin CR; Arrang JM; Schwartz JC; Schunack W J Med Chem; 2000 Oct; 43(21):3987-94. PubMed ID: 11052804 [TBL] [Abstract][Full Text] [Related]
15. New histamine H(3)-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency. Sasse A; Sadek B; Ligneau X; Elz S; Pertz HH; Luger P; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H J Med Chem; 2000 Aug; 43(17):3335-43. PubMed ID: 10966752 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of H3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chain. Barocelli E; Ballabeni V; Chiavarini M; Bertoni S; Mor M; Plazzi PV; Bordi F; Impicciatore M Inflamm Res; 2000 Apr; 49 Suppl 1():S62-3. PubMed ID: 10864424 [No Abstract] [Full Text] [Related]
19. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives. Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963 [TBL] [Abstract][Full Text] [Related]
20. A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines. Turner SC; Esbenshade TA; Bennani YL; Hancock AA Bioorg Med Chem Lett; 2003 Jul; 13(13):2131-5. PubMed ID: 12798320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]